跳至主要内容

Applications of Metabolite Identification and Structural Identification

 

Metabolite identification and structure identification have wide applications in many fields, including biomedicine, drug development, environmental monitoring, etc. This article will introduce the aspects of sample collection, separation and purification, detection and identification, structural analysis, biological function research, biomarker discovery, drug development and environmental monitoring for metabolite identification and structure identification. The MetID team of Medicilon is composed of experienced scientists. We provide fast and reliable in vivo and in vitro MetID and reactive metabolite capture services. We also support new drug screening and domestic and oversees IND filings. Since the establishment of MetID team, Medicilon has successfully completed multiple different types of research projects for clients, including challenging peptide MetID research.

1. Sample collection

The first step in metabolite identification and structure characterization is to collect the sample. Samples can be tissues, liquids, gases, etc. in living organisms, or they can be water samples, soil samples, gas samples, etc. in the environment. When collecting samples, attention should be paid to the representativeness and consistency of the samples, and the influence of sampling environment, time, location and other factors should be taken into consideration.

2. Separation and purification

The collected samples often contain a variety of metabolites and other impurities that require separation and purification. Commonly used separation and purification methods include chromatography, electrophoresis, precipitation, crystallization, etc. These methods can be selected and optimized based on the nature of the metabolites and the presence of impurities to ensure separation effectiveness and purity.

3. Testing and identification

The metabolites after separation and purification need to be detected and identified. Commonly used detection methods include mass spectrometry, nuclear magnetic resonance, infrared spectroscopy, etc. These methods can select appropriate detection methods based on the structure and properties of metabolites to obtain accurate identification results.

4. Structural analysis

The identified metabolites require structural elucidation to determine their chemical composition and structural characteristics. Commonly used structural analysis methods include quantum chemical calculations, X-ray crystal diffraction, hydrogen nuclear magnetic resonance spectroscopy, etc. These methods can provide detailed structural information of metabolites and provide basic data for subsequent biological function research and drug development.

5. Biological function research

Understanding the biological functions of metabolites is of great significance to understanding the life activities of organisms and the mechanisms of disease. By studying the biological functions of metabolites, new drug targets can be discovered or guidance for disease diagnosis and treatment can be provided. Commonly used biological function research methods include cell experiments, animal models, etc.

6. Biomarker discovery

Biomarkers refer to changes in certain substances in organisms under specific circumstances, which can reflect the physiological and pathological status of organisms. Through the study of metabolites, new biomarkers can be discovered for disease diagnosis, monitoring conditions and evaluating treatment effects. For example, certain tumor cells produce specific metabolites that can be used as markers for early diagnosis of tumors.

7. Drug research and development

Metabolite identification and structure characterization play an important role in drug development. Through the study of metabolites, new drug targets can be discovered and provide guidance for the development of new drugs. At the same time, metabolites can also be used as drug targets or key links in drug metabolism, providing a basis for the design and optimization of new drugs. For example, certain drugs can treat certain diseases by regulating metabolic processes.

8. Environmental monitoring

By monitoring metabolites in the environment, we can understand the status of environmental pollution and the health of the ecosystem. For example, by monitoring organic pollutants in water bodies, the degree of pollution in the water bodies and the health of the ecosystem can be assessed. At the same time, by studying metabolites in the environment, new environmental pollutants can also be discovered or provide guidance for environmental pollution control.

In summary, metabolite identification and structure identification have broad application value in many fields. Through research and practice in sample collection, separation and purification, detection and identification, structural analysis, biological function research, biomarker discovery, drug development and environmental monitoring, we can make important contributions to human health and environmental protection.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati